Management of Nonspecific Urethritis
For nonspecific (non-gonococcal) urethritis, treat with doxycycline 100 mg orally twice daily for 7 days as first-line therapy, NOT azithromycin 1 g, due to emerging resistance concerns with Mycoplasma genitalium. 1, 2
Diagnostic Approach
Before initiating treatment, confirm urethritis by documenting objective evidence of urethral inflammation through one of the following:
- Gram stain of urethral discharge showing ≥5 WBC per high-power field
- Positive leukocyte esterase test on first-void urine
- Microscopic examination of first-void urine sediment demonstrating ≥10 WBC per high-power field 1
All patients with confirmed or suspected urethritis must be tested for:
- Chlamydia trachomatis using NAAT
- Neisseria gonorrhoeae using NAAT
- Ideally Mycoplasma genitalium using NAAT (this significantly improves clinical outcomes) 2
Treatment Algorithm
First-Line Treatment (Confirmed Non-Gonococcal Urethritis)
Recommended Regimen:
Alternative Regimens (if doxycycline contraindicated):
- Erythromycin base 500 mg orally four times daily for 7 days
- Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
- Levofloxacin 500 mg orally once daily for 7 days
- Ofloxacin 300 mg orally twice daily for 7 days 1
If azithromycin must be used (compliance concerns), prescribe extended dosing:
- Azithromycin 500 mg stat, then 250 mg daily for 4 days (NOT the traditional 1 g single dose) 2
Critical Pitfall: Azithromycin Resistance
The traditional azithromycin 1 g single dose is NO LONGER recommended as first-line therapy due to:
- Development of antimicrobial resistance in M. genitalium 3, 2
- Neither azithromycin 1 g nor doxycycline achieves >90% cure rates for M. genitalium 3
- Recent guidelines explicitly advise against azithromycin to prevent further resistance 4, 2
When Diagnostic Tools Are Unavailable
If Gram-stain microscopy is not available, treat empirically with regimens effective against both gonorrhea and chlamydia 1
Patient Instructions
Sexual abstinence requirements:
- 7 days after single-dose therapy OR
- Until completion of 7-day regimen AND symptoms have resolved 1
- Until all sex partners are treated 1
Partner management:
- All sexual partners must be evaluated and treated 1
Additional testing:
- Screen for other STDs including syphilis and HIV 1
Management of Persistent Symptoms
If symptoms persist after treatment:
- Do NOT retreat based on symptoms alone without documentation of urethral inflammation 1
- Test for M. genitalium if not previously done 2
- Test for Trichomonas vaginalis in populations where prevalence >2% in symptomatic women 2
- Consider chronic prostatitis/chronic pelvic pain syndrome if persistent pain (perineal, penile, pelvic), irritative voiding symptoms, or pain during/after ejaculation lasting >3 months 1
Follow-Up Testing
- Test-of-cure NOT recommended for patients who received appropriate treatment unless therapeutic noncompliance or reinfection suspected 1
- Repeat testing at 6 months IS recommended due to high reinfection rates 1
Medication Dispensing
To maximize compliance:
- Dispense medications on-site in clinic
- Directly observe first dose 1